VSTM, US92337C2035

Verastem presents RAMP 201 data. Verastem stock trades at EUR 6.85 versus EUR 6.84.

Published on 10/05/2026 at 15:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit USD 40.08 million versus USD 22.88 million expected. Verastem stock costs EUR 6.85 on October 5, 2026 after EUR 6.84.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem (ISIN US92337C2035) was trading at EUR 6.85 at Lang & Schwarz on October 5, 2026 at 2:46 p.m. CEST, up 0.15 percent versus the prior close of EUR 6.84. On October 2, 2026, Verastem announced new RAMP 201 molecular profiling and external control-arm analyses for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

RAMP 201 data adds clinical detail

The October 2 release is the latest company event ahead of Verastem's October 14, 2026 research and development update for VS-7375. The program targets cancers driven by RAS/MAPK pathway abnormalities, while the RAMP 201 work focuses on recurrent low-grade serous ovarian cancer.

Investing.com reported that H.C. Wainwright reiterated a Buy rating and an USD 18.00 price target after new molecular analyses presented at the International Gynecologic Cancer Society meeting. The report cited an 18 percent confirmed overall response rate and 13-month median progression-free survival in a KRAS wild-type group.

Revenue beats the second-quarter forecast

Verastem reported USD 40.08 million of revenue in the second quarter of 2026, compared with a USD 22.88 million consensus estimate, according to MarketBeat. The company also reported an adjusted loss of USD 0.35 per share, narrower than the USD 0.43 expected loss.

That revenue comparison matters because the result combines product sales with licensing income, giving investors two different drivers to assess. Cash stood at USD 136.4 million on June 30, 2026, while operating cash flow was negative USD 43.9 million in the second quarter of 2026.

Analyst targets remain above the quote

MarketBeat said BTIG Research reaffirmed a Buy rating and an USD 18.00 target on October 5, 2026. The same report listed nine Buy ratings, one Hold rating and one Sell rating, with an average target of USD 13.83.

The targets are quoted in US dollars and therefore are not directly netted against the Lang & Schwarz euro price. The contrast is clear: clinical data and quarterly revenue support the story, while negative operating cash flow keeps financing discipline central to the investment case.

Verastem stock trades at EUR 6.85

Verastem stock was trading at EUR 6.85 at Lang & Schwarz on October 5, 2026 at 2:46 p.m. CEST, plus 0.15 percent versus the Lang & Schwarz prior close of EUR 6.84 on October 2, 2026.